Orbus Therapeutics Reports Positive Phase 3 STELLAR Trial Results for Eflornithine in Recurrent IDH-Mutant Astrocytoma
核心洞察
Orbus Therapeutics (搜索) will present updated Phase 3 STELLAR trial results showing eflornithine improves overall survival and progression-free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma (搜索).
Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase (搜索), a key enzyme in polyamine biosynthesis that is upregulated in certain cancers.
The drug has received FDA Orphan Drug Designation and Breakthrough Therapy Designation for anaplastic glioma (搜索) treatment, along with European Medicines Agency Orphan Medicinal Product status.
Orbus Therapeutics (搜索) announced it will present updated results from its Phase 3 STELLAR trial investigating eflornithine for recurrent WHO 2021 grade 3 IDH-mutant astrocytoma (搜索) at the Society for Neuro-Oncology Annual Meeting. The presentation, scheduled for November 22, 2025, will detail how eflornithine improved both overall survival and blinded independent central review-determined progression-free survival in this patient population.
Novel Mechanism Targets Cancer Cell Growth
Eflornithine represents a novel approach to cancer treatment as a cytostatic agent that irreversibly inhibits ornithine decarboxylase (搜索), a key enzyme in mammalian polyamine biosynthesis. This enzyme is upregulated in certain types of cancer, making it an attractive therapeutic target for oncology applications.
The drug has garnered significant regulatory attention, receiving Orphan Drug Designation and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for treating patients with anaplastic glioma (搜索). The European Medicines Agency has also granted Orphan Medicinal Product status for glioma (搜索) treatment through its Committee for Medicinal Products for Human Use.
Clinical Trial Presentation Details
Dr. Howard Colman, MD, PhD, FAAN, the Jon M. Huntsman Presidential Chair in Neuro-Oncology at the Huntsman Cancer Institute at the University of Utah, will present the updated STELLAR trial results. The presentation is titled "Updated results of Phase 3 STELLAR trial: Eflornithine improves overall survival and blinded independent central review determined progression free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma (搜索)."
The oral presentation will take place during the Clinical Trial Abstracts - Session II at the Hawaii Convention Center's Lili'u Theater 310, running from 11:09 a.m. to 11:14 a.m. on Saturday, November 22, 2025.
Addressing Rare Disease Treatment Gap
Orbus Therapeutics (搜索) positions itself as a late-stage, private biopharmaceutical company dedicated to developing products for rare diseases with few effective treatment options. Eflornithine serves as the company's lead product candidate, having completed one Phase 3 clinical study in patients with recurrent anaplastic astrocytoma (搜索), described as a rare form of central nervous system cancer.
The STELLAR trial results represent a significant milestone for patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma (搜索), a specific subset of brain tumors with limited therapeutic options. The demonstration of improved overall survival and progression-free survival outcomes could potentially address an important unmet medical need in neuro-oncology.